References
- Evans EG: Tinea pedis: clinical experience and efficacy of short treatment. Dermatology 1997;194(Suppl 1):3–6
- Korting HC, Rychlik R, Pfeil B. Treatment of interdigital tinea pedis: a systematic review. Dtsch Med Wochensch 2003;128:1819–24
- Meinhof W, Girardi RM, Stracke A. Patient non-compliance in dermatomycosis: results of a survey among dermatologists, general practitioners and patients. Dermatologica 1984;169 (Suppl 1):57–66
- Korting HC, Tietz H-J, Bräutigam M, et al. One week terbinafine 1% cream (Lamisil®) once daily is effective in the treatment of interdigital tinea pedis: a vehicle controlled study. Med Mycol 2001;39: 335–40
- Ryder NS, Favre B. Antifungal activity and mechanism of action of terbinafine. Rev Contemp Pharmacother 1997;8: 275–87
- Hill S, Thomas R, Smith SG, Finlay AY. An investigation of the pharmacokinetics of topical terbinafine (Lamisil®) 1% cream. Br J Dermatol 1992;127:396–400
- Alberti I, Kalia YN, Naik A, et al. Assessment and prediction of the cutaneous bioavailability of topical terbinafine, in vivo, in man. Pharm Res 2001;18:1472–5
- Topical dermatological drug product NDAs and ANDAs – in vivo bioavailability, bioequivalence, in vitro release and associated studies. United States Food and Drug Administration; June 1998
- Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev 1995;8:240–54
- Strober BE, Washenik K, Schupak JL. Principles of topical therapy. In: Burns T, Breathnatch S, Cox N, Griffiths C, eds. Rook’s Textbook of Dermatology, 7th edn. Oxford: Blackwell Science, 2004:2319–23
- Alberti I, Kalia YN, Naik A, et al. Effect of ethanol and isopropyl myristate on the availability of topical terbinafine in human stratum corneum, in vivo. Int J Pharm 2001; 219:11–19
- Weinstein GD, Van Scott EJ. Autoradiographic analysis of turnover times of normal and psoriatic epidermis. J Invest Dermatol 1965;45:257–62
- Nakashima T, Nozawa A, Majima T. A novel method using micropig stratum corneum in vitro for the evaluation of anti-Trichophyton mentagrophytes activity. Microbiol Immunol 2002;46:521–5
- Ortonne JP, Korting HC, Viguie-Vallanet C, et al. Efficacy and safety of a new single-dose terbinafine 1% formulation in patients with tinea pedis (athlete’s foot): a randomised, double-blind, placebo-controlled study. J Eur Acad Dermatol Venereol 2006;20: 1307–13